Trovagene Inc. (NASDAQ:TROV) rose 2.3% during mid-day trading on Wednesday . The stock traded as high as $5.46 and last traded at $5.33, with a volume of 117,342 shares. The stock had previously closed at $5.21.

A number of brokerages recently weighed in on TROV. Maxim Group reiterated a “buy” rating on shares of Trovagene in a report on Monday, June 6th. Cantor Fitzgerald raised shares of Trovagene from a “hold” rating to a “buy” rating and raised their target price for the company from $5.00 to $7.00 in a research report on Monday, August 8th. Leerink Swann reissued a “hold” rating on shares of Trovagene in a research report on Thursday, May 12th. Piper Jaffray Cos. reaffirmed a “hold” rating and issued a $5.00 price objective (down previously from $8.00) on shares of Trovagene in a research report on Thursday, May 12th. Finally, Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $7.13.

The company has a 50 day moving average price of $5.26 and a 200-day moving average price of $4.99. The company’s market capitalization is $150.74 million.

Trovagene (NASDAQ:TROV) last issued its earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. On average, equities analysts anticipate that Trovagene Inc. will post ($1.33) earnings per share for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.